ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,187.67
      0.00%
      US Tech 100
      17,585.60
      -0.15%
      Dow Jones
      39,056.39
      0.44%
      Brent Oil
      83.56
      0.84%
      Bitcoin
      61,147.52
      -1.90%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Sensei Biotherapeutics Inc (SNSE)

      7. Sensei Biotherapeutics Inc (SNSE) News

      SNSE

      Sensei Biotherapeutics (SNSE)

      Sensei Biotherapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:SNSE
      DateTimeSourceHeadlineSymbolCompany
      1:05PMiHub NewswireFeaturedElement79 Gold Corp Successfully Closes Maverick Springs Option Agreement
      03/05/20244:44PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
      02/28/20247:31AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
      02/16/20246:37PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
      02/16/20246:28PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
      02/16/20246:25PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
      02/08/20244:31PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
      01/04/20248:14AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
      11/07/20234:40PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNSESensei Biotherapeutics Inc
      11/07/20237:35AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
      11/07/20237:30AMGlobeNewswire Inc.Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:SNSESensei Biotherapeutics Inc
      11/06/20236:07AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
      11/03/20234:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
      11/03/20234:05PMGlobeNewswire Inc.Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual MeetingNASDAQ:SNSESensei Biotherapeutics Inc
      11/02/20234:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
      11/02/20234:50PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
      11/01/20237:30AMGlobeNewswire Inc.Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business OfficerNASDAQ:SNSESensei Biotherapeutics Inc
      10/25/20239:05AMGlobeNewswire Inc.Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual MeetingNASDAQ:SNSESensei Biotherapeutics Inc
      10/23/20237:30AMGlobeNewswire Inc.Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023NASDAQ:SNSESensei Biotherapeutics Inc
      10/20/20235:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
      09/27/20237:30AMGlobeNewswire Inc.Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®NASDAQ:SNSESensei Biotherapeutics Inc
      09/21/20237:30AMGlobeNewswire Inc.Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy ConferenceNASDAQ:SNSESensei Biotherapeutics Inc
      09/13/20238:43AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
      09/13/20237:30AMGlobeNewswire Inc.Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer ImmunotNASDAQ:SNSESensei Biotherapeutics Inc
      09/11/20235:34PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
      09/11/20235:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
      09/11/20235:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
      09/11/20235:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
      08/30/20237:30AMGlobeNewswire Inc.Sensei Biotherapeutics to Participate in Upcoming Investor ConferencesNASDAQ:SNSESensei Biotherapeutics Inc
      08/17/20235:15PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SNSESensei Biotherapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:SNSE